| Personalizing health care: feasibility and future implications B Godman, AE Finlayson, PK Cheema, E Zebedin-Brandl, ... BMC medicine 11, 1-23, 2013 | 126 | 2013 |
| Dabigatran–a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs RE Malmström, BB Godman, E Diogene, C Baumgärtel, M Bennie, ... Frontiers in pharmacology 4, 39, 2013 | 116 | 2013 |
| Essential to increase the use of generics in Europe to maintain comprehensive health care? B Godman, M Bennie, C Baumgärtel, L Sović-Brkičić, T Burkhardt, J Fürst, ... Farmeconomia. Health economics and therapeutic pathways 13 (3S), 5-20, 2012 | 64 | 2012 |
| Dabigatran-a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs B Godman, RE Malmström, E Diogene, S Jayathissa, S McTaggart, T Cars, ... Frontiers in pharmacology 5, 109, 2014 | 61 | 2014 |
| Generic drugs: quality, efficacy, safety and interchangeability D Tschabitscher, P Platzer, C Baumgärtel, M Müllner Wiener Klinische Wochenschrift 120, 63-69, 2008 | 50 | 2008 |
| What lessons can be learned from the launch of generic clopidogrel? C Baumgartel, B Godman, R Malmstrom, M Andersen, M Abuelkhair, ... Pro Pharma Communications International, 2012 | 49 | 2012 |
| Myths, questions, facts about generic drugs in the EU C Baumgärtel Generics and Biosimilars Initiative Journal (GaBI Journal) 1 (1), 34-8, 2012 | 45 | 2012 |
| Mini-review: medication safety of red yeast rice products A Farkouh, C Baumgärtel International Journal of General Medicine, 167-171, 2019 | 27 | 2019 |
| Sex-related differences in drugs with anti-inflammatory properties A Farkouh, C Baumgärtel, R Gottardi, M Hemetsberger, M Czejka, ... Journal of clinical medicine 10 (7), 1441, 2021 | 25 | 2021 |
| Generic pregabalin: current situation and implications for health authorities, generics and biosimilars manufacturers in the future B Goodman, M Wilcock, A Martin, J Fraeyman Generics and Biosimilars Initiative Journal 4 (3), 2015 | 24 | 2015 |
| Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study G Heinze, M Hronsky, B Reichardt, C Baumgärtel, M Müllner, A Bucsics, ... Applied health economics and health policy 13, 193-205, 2015 | 23 | 2015 |
| Initiatives to increase the prescribing of low cost generics: the case of Scotland in the international context B Godman, A Kurdi, A Leporowski, A Morton, C Baumgärtel, T Bochenek, ... Medical Research Archives 5 (3), 2017 | 20 | 2017 |
| Are generic immunosuppressants safe and effective? B Godman, C Baumgärtel Bmj 350, 2015 | 17 | 2015 |
| Prevalence and determinants of unintended double medication of antihypertensive, lipid‐lowering, and hypoglycemic drugs in Austria: a nationwide cohort study G Heinze, LM Jandeck, M Hronsky, B Reichardt, C Baumgärtel, A Bucsics, ... Pharmacoepidemiology and Drug Safety 25 (1), 90-99, 2016 | 15 | 2016 |
| Bioequivalence of narrow therapeutic index drugs and immunosuppressives C Baumgärtel, B Godman Generics and Biosimilars Initiative Journal 4 (4), 2015 | 9 | 2015 |
| Generika: qualität, wirksamkeit, sicherheit und austauschbarkeit D Tschabitscher, P Platzer, C Baumgärtel, M Müllner Wien Klin Wochenschr 120 (63), 9, 2008 | 8 | 2008 |
| Generic clopidogrel–the medicines agency’s perspective C Baumgärtel Generics Biosimilars Initiat J 1, 89-91, 2012 | 6 | 2012 |
| Austria increases dialogue in order to involve physicians more with biosimilars C Baumgartel GaBI Journal 2, 8, 2013 | 4 | 2013 |
| Interpreting the Benefit and Risk Data in Between-Drug Comparisons: Illustration of the Challenges Using the Example of Mefenamic Acid versus Ibuprofen A Farkouh, M Hemetsberger, CR Noe, C Baumgärtel Pharmaceutics 14 (10), 2240, 2022 | 3 | 2022 |
| Substantial savings with generics in Austria–and still room for more C Baumgärtel GaBI Journal 4 (3), 2, 2015 | 3 | 2015 |
